Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

Publish date: June 2019

Login to access report

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm. Roche / Genentech’s Ocrevus, Merck Serono’s Mavenclad, and a growing array of next-generation compounds from Novartis, Celgene, Actelion/Janssen, Biogen, Genmab, and TG Therapeutics will intensify competition in the saturated relapsing MS market. Meanwhile, Ocrevus continues to transform treatment in the underserved PP-MS population, and developers like MediciNova (with its intriguing candidate ibudilast) and Biogen (opicinumab) have renewed focus on developing neuroprotective or reparative treatments in MS—now the “next frontier” in a market replete with reliable anti-inflammatory options. Separately, the looming entry of oral generics will mark a historic shift in this high-cost market and limit the market potential for follow-ons as reimbursement authorities race to rein in healthcare costs. Understanding these intersecting forces will be key to the success of current and future players in this evolving market.

Questions Answered:

  •  What is the commercial outlook for Ocrevus, Mavenclad, and Mayzent compared with other potent DMTs? What impact will Ocrevus have in the progressive MS market, specifically?
  • How will generic competition shape the MS market, and when will it occur?
  • What clinical roles will entrenched platform injectables, current and next-generation orals, and MAbs play in the evolving MS treatment algorithm?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • November 2018
      • September 2018
      • June 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Sclerosis?
        • What Factors Are Constraining the Market for Multiple Sclerosis?
      • Drug-Class-Specific Trends
        • Recombinant IFN-βs
        • Polypeptides
        • Integrin Antagonists
        • S1P Receptor Modulators
        • Pyrimidine Synthesis Inhibitors
        • Nrf2 Pathway Activators
        • Anti-CD52 MAbs
        • Anti-CD20 MAbs
        • Oral Immunosuppressants
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Natural History
      • Etiology
      • Pathophysiology
      • Key Pathways and Drug Targets
        • Inflammation/Autoimmune Attack
        • Demyelination and Inhibition of Remyelination
        • Neurodegeneration
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Multiple Sclerosis
        • Drug-Treated Cases of Multiple Sclerosis
        • Subpopulations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Interferon-Betas
        • Polypeptides
        • Integrin Antagonists
        • Sphingosine-1-Phosphate Receptor Modulators
        • Pyrimidine Synthesis Inhibitors
        • Nrf2 Pathway Activators
        • Anti-CD52 Monoclonal Antibodies
        • Anti-CD20 Monoclonal Antibodies
        • Oral Immunosuppressants
      • Medical Practice
        • Overview
        • Risk of PML with MS DMTs
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Multiple Sclerosis
    • Emerging Therapies
      • Key Findings
        • Pipeline Overview
      • Key Emerging Therapies
        • Sphingosine-1-Phosphate Receptor Modulators
        • Anti-CD20 Monoclonal Antibodies
        • Tyrosine Kinase Inhibitors
        • Phosphodiesterase Inhibitors
        • Anti-LINGO-1 Monoclonal Antibodies
        • Nrf2 Pathway Activators
        • Vitamins
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Multiple Sclerosis Bibliography

Author(s): Sarah Soucy; Sunali D. Goonesekera, SM

Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.